Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel (LN-144/LN-145/LN-145-S1) in Solid Tumors
NCT03645928Phase 2Terminated
- Sponsor
- Iovance Biotherapeutics
- Start
- May 2019
- Primary completion
- Feb 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 7
01
Overview
A Phase 2 trial of lifileucel in melanoma, squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung cancer (NSCLC), sponsored by Iovance Biotherapeutics. Started May 2019; status: terminated.
02
Drugs
lifileucel
03
Conditions
melanomasquamous cell carcinoma of the head and neck (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03645928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645928.